Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Esketamine Shows Promise in Depression Studies

Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.

Read More »

Madrigal Pharma reports liver drug study success

Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.

Read More »

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Read More »

Novo Nordisk’s oral diabetes drug beats Jardiance in study

Novo Nordisk said data from a large final-stage study of a pill the company hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.

Read More »

Genmab, Johnson & Johnson Halt Lung Cancer Study

Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.

Read More »

Roche notches another lung cancer win

Roche’s bid to keep Merck’s cancer blockbuster Keytruda within striking distance got a lift when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients’ survival.

Read More »

AstraZeneca cancer drug hits second goal by extending survival

AstraZeneca’s immunotherapy drug Imfinzi hit a second important goal by improving overall survival in lung cancer patients.

Read More »

Keytruda succeeds in late-stage lung cancer study

Merck & Co.’s cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.

Read More »

Sesen Bio Shares Plunge Despite Reporting Positive Interim Phase III Results

Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.

Read More »

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc’s potential new antibiotic to treat a common form of pneumonia met the main goal of a key clinical trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom